Intercept Pharmaceuticals : Announces Positive Data in Fibro

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid


OCA 25 mg met the agreed primary endpoint of... | July 7, 2022

Related Keywords

, Nareg Sagherian , Karen Preble , Exchange Commission , Linkedin , Global Corporate Communications , Intercept Pharmaceuticals Inc , Twitter , Securities Exchange , Nasdaq , Intercept Announces Positive Data , New Analysis , Obeticholic Acid , Analysis Methodology , Randomized Global Phase , Obeticholic Acid Treatment , Liver Fibrosis , New Drug Application , Securities Act , Securities Exchange Act , Annual Report , Quarterly Report , Executive Director , Global Investor Relations , Intercept Pharmaceuticals , Nc Stock Exchange , News , Information , Press Release , Intercept , Nnounces , Positive , Data , N , Ibrosis , Ue , O , Cash , Rom , Few , Analysis , F , Its , Hase , Regenerate , Study , Beticholic , Acid , Ca , 5 , G , Pet , The , Greed , Primary , Ndpoint Icpt Us45845p1084 ,